
A-71623CCK1 agonist |
Sample solution is provided at 25 µL, 10mM.
































Quality Control & MSDS
- View current batch:
- Purity = 98.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure


A-71623 Dilution Calculator
calculate

A-71623 Molarity Calculator
calculate
Cas No. | 130408-77-4 | SDF | Download SDF |
Chemical Name | (6S,9S,12S)-6-((1H-indol-3-yl)methyl)-12-(((S)-1-amino-1-oxo-3-phenylpropan-2-yl)(methyl)carbamoyl)-2,2-dimethyl-4,7,10-trioxo-9-(4-(3-(o-tolyl)ureido)butyl)-3-oxa-5,8,11-triazatetradecan-14-oic acid | ||
Canonical SMILES | O=C([C@H](CCCCNC(NC1=CC=CC=C1C)=O)NC([C@H](CC2=CNC3=CC=CC=C23)NC(OC(C)(C)C)=O)=O)N[C@@H](CC(O)=O)C(N(C)[C@H](C(N)=O)CC4=CC=CC=C4)=O | ||
Formula | C44H56N8O9 | M.Wt | 840.97 |
Solubility | Soluble to 1 mg/ml in 20mM PBS buffer | Storage | Desiccate at -20°C |
Physical Appearance | White lyophilised solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. |
A-71623 is a selective agonist of CCKA receptor with an IC50 value of 3.7 nM in guinea pig pancreas [1, 2].
CCKA receptors belong to a subtype of cholecystokinin (CCK) receptors in the brain. CCK is a type of neuropeptide present throughout the central nervous system. CCK can act as a neurotransmitter in both normal and abnormal brain. CCK receptors exist in two forms in the brain. Another subtype of CCK receptors is CCKB subtype [1].
In NCI-H345 cells possessing CCKB/gastrin receptors, A-71623 was weak and behaved as a partial agonist in calcium studies [2]. A-71623 had very low affinity to CCK binding sites in C6 cells with an IC50 value of 1236 ± 81 nM [3]. It is hard to find the CCKA response result of the application of A-71623 in cells.
In radioligand binding assays, A-71623 showed IC50 values of 3.7 nM for CCKA in guinea pig pancreas and 4500 nM for CCKB in cerebral cortex. Data showed that A-71623 was an agonist in stimulating the release of pancreatic amylase, and this stimulatory effect was potently inhibited by L-364,718, a CCKA antagonist. Data showed that A-71623 acted as a full agonist in stimulating the breakdown of phosphoinositide in pancreas. In the ileum, A-71623 was also a potent agonist in stimulating CCKA receptors. In guinea pig gastric glands, the affinity of A-71623 for the CCK-B/gastrin receptor was 11 µM. This result demonstrated that A-71623 should be a potent and selective agonist at CCKA receptors [2].
References: [1]. Gracey DJ, Bell R, King DJ. Differential effects of the CCKA receptor ligands PD-140,548 and A-71623 on latent inhibition in the rat. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2002, 26(3): 497-504.[2]. Lin CW, Shiosaki K, Miller TR, et al. Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors. Molecular pharmacology, 1991, 39(3): 346-351.[3]. Kaufmann R, Lindschau C, Scho T, et al. Type B cholecystokinin receptors on rat glioma C6 cells. Binding studies and measurement of intracellular calcium mobilization. Brain research, 1994, 639(1): 109-114.
ebiomall.com






>
>
>
>
>
>
>
>
>
>
>
1.若都为正常,那么并未有太大问题,只要定期复查就可以了。
2.如果TGAb、TMAb、甲状腺功能均高,那么就是桥本氏甲状腺炎并甲亢,需要抗甲亢治疗。
3.如果TGAb、TMAb高,甲状腺功能下降,那么就是桥本氏甲状腺炎并甲减,需要进行甲减治疗。
4.如果TGAb、TMAb高,甲状腺功能正常,那么就是桥本氏甲状腺炎,无需特殊治疗,只要定期复查甲状腺功能就可能以了,不过这种情况有可能以后演变成甲减或者甲亢。
1.若都为正常,那么并未有太大问题,只要定期复查就可以了。
2.如果TGAb、TMAb、甲状腺功能均高,那么就是桥本氏甲状腺炎并甲亢,需要抗甲亢治疗。
3.如果TGAb、TMAb高,甲状腺功能下降,那么就是桥本氏甲状腺炎并甲减,需要进行甲减治疗。
4.如果TGAb、TMAb高,甲状腺功能正常,那么就是桥本氏甲状腺炎,无需特殊治疗,只要定期复查甲状腺功能就可能以了,不过这种情况有可能以后演变成甲减或者甲亢。
(Hypertension,2004,43:297-305)
2月5日 过氧化物酶体增生物激活受体γ(PPARγ)是一种属于核激素受体超家族的配体激活转录因子。在巨噬细胞、内皮细胞和血管平滑肌细胞中均有表达。它调节与脂质代谢、血管炎症和促成动脉粥样硬化及血管成形术后再狭窄的增生有关的主要蛋白的基因表达。PPARγ合成配体的发现加深了人们对其配体依赖性激活和之后的生物效应机制的认识,特别是有关PPARγ在血管病理生理学中作用的认识。噻唑烷二酮PPARγ激动剂不仅改善了2型糖尿病患者的胰岛素耐药性,而且在离体情况下或动脉粥样硬化动物模型中均有广谱的抗动脉粥样硬化效应。
美国加州大学洛杉矶分校的Willa A. Hsueh博士及其同事总结了PPARγ作为噻唑烷二酮分子靶点的重要作用以及在控制血管炎症和心血管系统增生方面的意义。
Peroxisome Proliferator-Activated Receptor: Implications for Cardiovascular Disease
Willa A. Hsueh; Dennis Bruemmer
From Division of Endocrinology, Diabetes, and Hypertension, David Geffen School of Medicine, University of California, Los Angeles.
Correspondence to Willa A. Hsueh, Division of Endocrinology, Diabetes, and Hypertension, David Geffen School of Medicine, University of California, Los Angeles Warren Hall, Suite 24–130, 900 Veteran Avenue, Los Angeles, CA 90095. E-mail whsueh@mednet.ucla.edu
Abstract
Peroxisome proliferator-activated receptor(PPAR ) is a ligand-activated transcription factor belonging to the nuclear hormone receptor superfamily. PPARis expressed by macrophages, endothelial cells, and vascular smooth muscle cells. It regulates gene expression of key proteins involved in lipid metabolism, vascular inflammation, and proliferation contributing to atherogenesis and postangioplasty restenosis. The discovery of synthetic ligands for PPARhas led to significant enhancement of our understanding of the mechanism of their ligand-dependent activation and subsequent biological effects, particularly with respect to the role of PPARin vascular pathophysiology. The thiazolidinedione PPARagonists not only improve insulin resistance in patients with type II diabetes but also exert a broad spectrum of antiatherogenic effects in vitro and in animal models of atherosclerosis. In this review, we summarize the important role of PPARas a molecular target for thiazolidinediones and its implications for the control of vascular inflammation and proliferation for the cardiovascular system.
Key Words: atherosclerosis • diabetes mellitus • peroxisome proliferator-activated receptor • angiotensin • inflammation
相关链接:http://hyper.ahajournals.org/cgi/content/abstract/43/2/297?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=PPAR&searchid=1076561399333_3746&stored_search=&FIRSTINDEX=0&volume=43&issue=2&search_url=http%3A%2F%2Fhyper.ahajournals.org%2Fcgi%2Fsearch&journalcode=hypertensionaha

